

Ambulatory Cardiac Event Monitoring

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Summary

Irregular heart rhythms, known as arrhythmias, can present with symptoms such as dizziness, fainting, palpitations, chest pain, or no symptoms at all. The Plan members with a suspected arrhythmia may require ambulatory monitoring to help make an accurate diagnosis when hospital or office-based evaluations have not revealed any abnormalities. A traditional electrocardiogram (ECG) evaluates the heart over a single point in time, providing only a short interval to detect an abnormal rhythm. Cardiac event monitors address this limitation by recording the cardiac activity over longer periods of time to detect abnormalities that may occur infrequently. There are several different types of portable cardiac monitoring devices. Some of these devices record the heart rhythm from outside the body using small electrodes placed over the chest, while others are implanted just under the skin. They also vary based on the level of patient interaction required and the method of recording or transmitting data. This guideline discusses the clinical criteria for external and internal loop recorders, continuous ambulatory monitors, and mobile cardiac telemetry.

This guideline does not outline Holter monitoring; please refer to MCG A-0120 clinical criteria for medical necessity.

Definitions

"Cardiac Arrhythmia" refers to an abnormal or irregular heart rhythm (e.g., atrial fibrillation, heart block, etc.).

“Holter Monitor” refers to an external device that continuously records the heart rhythm for 24-48 hours (up to 2 weeks with newer models) with 12 leads similar to an ECG, typically in the setting of arrhythmias or symptoms that occur at least daily.

“Continuous Ambulatory Monitor (e.g., Zio by iRhythm)” refers to a device that records the heart rhythm continuously, similar to a Holter monitor, but for durations of time up to 14 days and with only a single lead.

“External Loop Recorder” refers to a device that is worn continuously but only records data when triggered by patient interaction (often via pushing a button on the device) or a built-in algorithm that detects an abnormal rhythm. Patients are instructed to activate the device when they experience symptoms of the arrhythmia, resulting in the recording of a few minutes prior to, during, and after the triggering. This device can be used for up to 6 weeks. External loop recorders can also have a real-time data transmission and analysis function when triggered, and differ from “mobile cardiac telemetry” in that the recording and data transmission is not continuous.

“Implantable Loop Recorder” or “Insertable Cardiac Monitor” refers to a device similar to an external loop recorder except that it is implanted just under the skin for longer term monitoring and to allow the patient to resume daily activities. This device can be left in place for up to 3 years in some cases.

“Mobile Cardiac Telemetry” refers to continuous recording or automatically-triggered recording devices that transmit the cardiac rhythm in real-time to a data center for evaluation typically up to 30 days. The real-time data transmission allows the rhythm to be immediately analyzed and the treating physician to be notified for intervention.

**Note: There are also devices that combine multiple classes of event monitors, such as functioning as a Holter monitor for the first 24-48 hours and then being automatically converted to a mobile cardiac telemetry device if the initial period was non-diagnostic.*

“Atrial Fibrillation” (AF) is the most common arrhythmia in adults and can be classified as paroxysmal, persistent, long-standing persistent, or permanent.

- “Paroxysmal AF” refers to AF that is intermittent and terminates within 7 days of onset. Paroxysmal AF is unique in that the rhythm alternates between AF and another rhythm, often spontaneously and at unpredictable intervals. Because of the risk of thrombus and subsequent embolism, potentially leading to stroke, cardiac monitoring may be indicated in some individuals with suspected paroxysmal AF.
- “Persistent AF” refers to AF that is continuous for more than 7 days.
- “Long-standing persistent AF” refers to AF that is continuous for more than 12 months.
- “Permanent AF” is when an individual and their healthcare provider jointly agree to accept AF as a long-term condition and stop further attempts to restore normal rhythm.

“Cryptogenic Stroke” is a type of ischemic stroke (caused by a blockage in a blood vessel supplying the brain) where no clear cause or risk factors have been identified. Roughly one-third of ischemic strokes are cryptogenic and may be due to paroxysmal atrial fibrillation.

A. Clinical Indications

1. Medical Necessity Criteria for Clinical Review

a. Indication-Specific Criteria

2. Experimental or Investigational / Not Medically Necessary

B. Applicable Billing Codes

C. References

Medical Necessity Criteria for Clinical Review

Indication-Specific Criteria

External Loop Recorders (External Event Monitor)

The Plan considers external loop recorders medically necessary for cardiac event monitoring when any ONE of the following criteria is met:

1. To document an arrhythmia or to evaluate symptoms suggestive of cardiac arrhythmia (e.g., syncope, presyncope, lightheadedness, and/or palpitations) in:
 - a. Members with non-diagnostic Holter monitoring; *or*
 - b. Members with symptoms that occur so infrequently (i.e., less often than every 48 hours) or the suspected arrhythmia is such that Holter monitor would be unlikely to be diagnostic; *or*
2. Members with cryptogenic stroke who have had a negative workup for atrial fibrillation including at least a 24-hour non-diagnostic Holter monitor, and where results are intended to guide anticoagulation decisions.

Continuous Ambulatory Recorders (e.g., Zio monitor, Zio patch by iRhythm)

The Plan considers continuous ambulatory recorders medically necessary for cardiac event monitoring when ALL of the following criteria are met:

1. Members 18 years of age or older; *and*
2. The recorder is needed for ONE of the following situations:
 - a. To document an arrhythmia or to evaluate symptoms suggestive of cardiac arrhythmia (e.g., syncope, presyncope, lightheadedness, and/or palpitations) in:
 - i. Members with non-diagnostic Holter monitoring within the last 60 days; *or*
 - ii. Members with symptoms that occur so infrequently (i.e., less often than every 48 hours) or the suspected arrhythmia is such that Holter monitor would be unlikely to be diagnostic; *or*
 - iii. Members with hospitalization-based telemetry monitoring within the last 60 days that failed to identify a diagnosis; *or*

- b. Members with cryptogenic stroke who have had a negative workup for atrial fibrillation including at least a 48-hour non-diagnostic Holter monitor, and where results are intended to guide anticoagulation decisions; *or*
- c. Members with hypertrophic cardiomyopathy (HCM) who meet the following criteria and aligned with AHA/ACC/AMSSM/HRS/PACES/SCMR guideline:
 - i. In members with HCM who are deemed to be at high risk for developing atrial fibrillation (AF) based on the presence of risk factors or as determined by a validated risk score, and who are eligible for anticoagulation, extended ambulatory monitoring is recommended to screen for AF as part of initial evaluation and annual follow-up; *and*
- 3. There is no current use of any devices that may impact electrical signal detection, including but not limited to:
 - a. Wearable external defibrillator/cardioversion
 - b. Neurostimulator

Implantable Loop Recorders / Insertable Cardiac Monitors

The Plan considers implantable loop recorders medically necessary for cardiac event monitoring when ALL of the following criteria are met:

- 1. The procedure and monitoring are ordered by a licensed cardiologist; *and*
- 2. The member meets at least ONE of the following criteria:
 - a. Members with cryptogenic stroke who have had a negative workup for atrial fibrillation including at least a 48-hour non-diagnostic Holter monitor or inpatient telemetry, and where the results are intended to guide anticoagulation decisions; *or*
 - b. To evaluate recurrent, unexplained symptoms suggestive of cardiac arrhythmia (e.g., syncope, presyncope, lightheadedness, and/or palpitations) in ONE of the following:
 - i. Members with structural heart disease, prior myocardial infarction, or significant clinical or ECG features* when noninvasive ambulatory monitoring with 30-day external loop recorder or mobile cardiovascular telemetry has been non-diagnostic; *or*
 - ii. Members without structural heart disease, prior myocardial infarction, or significant clinical or ECG changes* when the symptoms occur so unpredictably or infrequently (i.e., less often than once per month) or the suspected arrhythmia is such that noninvasive ambulatory monitoring with 30-day external loop recorder or mobile cardiovascular telemetry has been non-diagnostic.
 - 1. Symptoms must be frequent enough to have a high likelihood of capture within the battery longevity of the device (typically 2 - 3 years);
 - c. Members with hypertrophic cardiomyopathy (HCM) who meet the following criteria and aligned with AHA/ACC/AMSSM/HRS/PACES/SCMR guideline:

- i. In members with HCM who are deemed to be at high risk for developing atrial fibrillation (AF) based on the presence of risk factors or as determined by a validated risk score, and who are eligible for anticoagulation, extended ambulatory monitoring is recommended to screen for AF as part of initial evaluation and annual follow-up.

* Significant clinical or ECG features defined as any one or more of the following:

- Exertional syncope or syncope upon standing
- Syncope associated with palpitations
- Family history of sudden cardiac death
- Short QTc interval: < 370 ms or long QTc interval: > 440 ms (men) or >460 ms
- Heart rate < 50 beats per minute or sinoatrial block in the absence of influencing medications/substances or athletic lifestyle
- Non-sustained ventricular tachycardia
- Bifascicular block or other intraventricular conduction abnormalities
- Brugada pattern with ST elevations in V1-V3 and RBBB pattern

Removal/Replacement of Implantable Loop Recorders/Insertable Cardiac Monitors

The Plan considers the removal or replacement of implantable loop recorders as medically necessary if ONE of the following is met, including but not limited to:

1. Infection at the surgical site, device sensitivity, device migration, erosion of the device; *or*
2. Device malfunction or past warranty.

Mobile Cardiac Telemetry

The Plan considers mobile cardiac telemetry medically necessary for cardiac event monitoring when ALL of the following criteria are met:

1. The device and monitoring are ordered by a licensed cardiologist; *and*
2. The member meets at least ONE of the following criteria:
 - a. To document an arrhythmia or to evaluate symptoms suggestive of cardiac arrhythmia (e.g., syncope, presyncope, lightheadedness, and/or palpitations) in members with non-diagnostic Holter monitoring, continuous ambulatory monitor, and/or 48 hours of continuous telemetry; *or*
 - b. For evaluation of members with suspected atrial fibrillation as the cause of cryptogenic stroke who have had non-diagnostic Holter monitor, ambulatory event monitor, and/or 48 hours of continuous telemetry; *or*
 - c. Members with hypertrophic cardiomyopathy (HCM) who meet the following criteria and aligned with AHA/ACC/AMSSM/HRS/PACES/SCMR guideline:
 - i. In members with HCM who are deemed to be at high risk for developing atrial fibrillation (AF) based on the presence of risk factors or as determined by a validated risk score, and who are eligible for anticoagulation, extended

ambulatory monitoring is recommended to screen for AF as part of initial evaluation and annual follow-up.

Mobile cardiac telemetry for greater than 30 days requires documentation of continued medical necessity and is subject to review.

Experimental or Investigational / Not Medically Necessary

Cardiac event monitoring for any other indication not meeting the Indication-Specific Criteria is NOT considered medically necessary by the Plan, as it is considered experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

1. Applicable to all cardiac event monitors:
 - a. Monitoring for asymptomatic episodes of atrial fibrillation in assessment of response to pharmacologic treatment
 - b. Monitoring for arrhythmias without any suggestive symptoms or when other potential causes have not been ruled out and/or treated appropriately
 - c. Monitoring for ST segment depression and/or suspected myocardial ischemia
 - d. Monitoring for effectiveness of pharmacologic treatment of arrhythmias
 - e. Monitoring for recurrence of arrhythmias after discontinuation of pharmacologic treatment
2. Applicable to implantable loop recorders only:
 - a. Monitoring for episodes (symptomatic or asymptomatic) of atrial fibrillation (AF) after catheter or surgical ablation
 - i. *Rationale:* The current data is contradictory, with some studies suggesting a significant benefit in the rate of AF detection and others finding no net benefit. The ABACUS study (2013) looked at 44 patients undergoing ablation for AF who received an implantable loop recorder (ILR) simultaneous to conventional monitoring. While the ILR detected significantly more events of AF, 51% of episodes were false positives. This high rate of false positives has been documented in several other studies. The authors conclude that further research is needed to guide clinical management. At this time, the available evidence is insufficient to determine whether the benefits of implantable loop recorder placement outweigh the risks for this indication.
3. Applicable to mobile cardiac telemetry (MCT) only:
 - a. Monitoring for effectiveness of pharmacologic treatment of arrhythmias
 - i. *Rationale:* Olson et al (2007) conducted a case series evaluating the mobile cardiac telemetry for efficacy of antiarrhythmic control of arrhythmias. The study was limited by a small sample size (n=29 for this specific subgroup), and it was uncontrolled with no comparison to other monitoring devices. The current literature is insufficient to determine the benefit of MCT in this population.
 - b. Monitoring for persistent atrial fibrillation after cardiac ablation

- i. *Rationale:* Vasamreddy et al (2006) examined 19 patients, who used a mobile cardiac telemetry system 5 days per month for 6 months to evaluate for persistent AF. Only 10 patients completed the study and it was limited by a lack of long-term follow-up and now comparison to other monitoring devices. The current literature is insufficient to determine the benefit of MCT in this population.

The following devices or monitoring technologies are NOT considered medically necessary by the Plan, as they are considered experimental, investigational, or unproven due to lack of peer-reviewed clinical evidence. Non-covered devices include, but are not limited to, the following:

1. eCardio eVolution
2. Mobile phone or mobile applications based cardiac monitoring platforms, including but not limited to:
 - a. AliveCor Heart Monitor (iPhoneECG)
 - b. iHeart/Kardia Mobile
 - c. Any other mobile phone based device or "app" used to record or monitor cardiac rhythm
3. ViSi Mobile Monitoring System
4. Biotronik BioMonitor
5. BodyGuardian Remote Monitoring System
6. CardioPatch
7. CardioKey
8. LifeWatch LifeStar ACT Ex service
9. AngelMed Guardian implantable device for intracardiac ischemia monitoring
 - a. *Rationale:* Study terminated after safety concerns and voted against unanimously by FDA board of advisors.

Applicable Billing Codes

Table 1	
External Loop Recorders (External Event Monitor)	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
93268	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; includes transmission, review and interpretation by a physician or other qualified healthcare professional

93270	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; recording (includes connection, recording, and disconnection)
93271	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; transmission and analysis
93272	External patient and, when performed, auto activated electrocardiographic rhythm derived event recording with symptom-related memory loop with remote download capability up to 30 days, 24-hour attended monitoring; review and interpretation by a physician or other qualified health care professional

Table 2	
Continuous Ambulatory Recorders (e.g., Zio monitor, Zio patch by iRhythm)	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
93241	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation
92342	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)
93243	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; scanning analysis with report
93244	External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation
93245	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; includes recording, scanning analysis with report, review and interpretation
93246	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)
93247	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; scanning analysis with report

93248	External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation
-------	--

Table 3	
Mobile Cardiac Telemetry	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
93228	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified healthcare professional
93229	External mobile cardiovascular telemetry with electrocardiographic recording, concurrent computerized real time data analysis and greater than 24 hours of accessible ECG data storage (retrievable with query) with ECG triggered and patient selected events transmitted to a remote attended surveillance center for up to 30 days; technical support for connection and patient instructions for use, attended surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional

Table 4	
ICD-10 codes considered medically necessary with Table 1, 2, or 3 codes if criteria are met, including but not limited to:	
<i>Code</i>	<i>Description</i>
I42.0	Dilated cardiomyopathy
I42.1	Obstructive hypertrophic cardiomyopathy
I42.2	Other hypertrophic cardiomyopathy
I44.0 - I44.7	Atrioventricular and left bundle-branch block
I45.0 - I45.9	Other conduction disorders
I47.0 - I47.9	Paroxysmal tachycardia
I48.0 - I48.92	Atrial fibrillation and flutter
I49.01 - I49.9	Other cardiac arrhythmias
I63.00 - I63.9	Cerebral infarction

R00.0	Tachycardia, unspecified
R00.1	Bradycardia, unspecified
R00.2	Palpitations
R42	Dizziness and giddiness
R55	Syncope and collapse
Z82.41	Family history of sudden cardiac death
Z86.73	Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits

Table 5	
Implantable Loop Recorders	
CPT/HCPCS codes considered medically necessary if criteria are met:	
<i>Code</i>	<i>Description</i>
0650T	Programming device evaluation (remote) of subcutaneous cardiac rhythm monitor system, with iterative adjustment of the implantable device to test the function of the device and select optimal permanently programmed values with analysis, review and report by a physician or other qualified health care professional
33285	Insertion, subcutaneous cardiac rhythm monitor, including programming
33286	Removal, subcutaneous cardiac rhythm monitor
93285	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified healthcare professional; implantable loop recorder system
93291	Interrogation device evaluation (in person) with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter; implantable loop recorder system, including heart rhythm derived data analysis
93297	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, including analysis of 1 or more recorded physiologic cardiovascular data elements from all internal and external sensors, analysis, review(s) and report(s) by a physician or other qualified health care professional

93298	Interrogation device evaluation(s), (remote) up to 30 days; implantable loop recorder system, including analysis of recorded heart rhythm data, analysis, review(s) and report(s) by a physician or other qualified healthcare professional
C1764	Event recorder, cardiac (implantable)
E0616	Implantable cardiac event recorder with memory, activator and programmer

References

1. Barrett PM, Komatireddy R, Haaser S et al. Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. *Am J Med* 2014; 127(1):95 e11-7.
2. Bernstein, R. A., Kamel, H., Granger, C. B., Piccini, J. P., Sethi, P. P., Katz, J. M., Vives, C. A., Ziegler, P. D., Franco, N. C., Schwamm, L. H., Acosta, I., Jamnadas, P., Manda, S., Alimohammad, R., Arias, V., Tempore, K., Ward, K., Asi, K., Choudhuri, I., . . . Neisen, K. (2021). Effect of Long-term Continuous Cardiac Monitoring vs Usual Care on Detection of Atrial Fibrillation in Patients With Stroke Attributed to Large- or Small-Vessel Disease. *JAMA*, 325(21), 2169. <https://doi.org/10.1001/jama.2021.6470>
3. Björkenheim A, Brandes A, Chemnitz A, Magnuson A, Edvardsson N, Poçi D. Rhythm Control and Its Relation to Symptoms during the First Two Years after Radiofrequency Ablation for Atrial Fibrillation. *Pacing Clin Electrophysiol*. 2016;39(9):914-25.
4. Bolourchi M, Batra AS. Diagnostic yield of patch ambulatory electrocardiogram monitoring in children (from a national registry). *Am J Cardiol*. Mar 1 2015;115(5):630-634. PMID 25591894
5. Caplan LR. Overview of the evaluation of stroke. UpToDate.com. Last updated April 29, 2022. Retrieved on June 2022 from https://www.uptodate.com/contents/overview-of-the-evaluation-of-stroke?sectionName=Monitoring%20for%20subclinical%20atrial%20fibrillation&search=implantable%20loop%20recorder&topicRef=958&anchor=H24817210&source=see_link#H24817210
6. Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. *Circulation*. 2020;141(16):e750-e772. Doi: <https://doi.org/10.1161/CIR.0000000000000748>
7. Choy AV, Srinivasan C. Mobile Cardiac Telemetry in Evaluation of Children Presenting with Paroxysmal Symptoms Suggestive of Tachyarrhythmia: Comparison to Conventional Methods of Ambulatory Electrocardiographic Monitoring. *Journal of the American College of Cardiology*. 2020;75(11). Doi:10.1016/S0735-1097(20)31262-6
8. Culebras A, Messe SR, Chaturvedi S et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2014; 82(8):716-24.
9. Derkac, W. M., Finkelmeier, J. R., Horgan, D. J., & Hutchinson, M. D. (2017). Diagnostic yield of asymptomatic arrhythmias detected by mobile cardiac outpatient telemetry and autotrigger looping event cardiac monitors. *Journal of cardiovascular electrophysiology*, 28(12), 1475-1478.

10. Dussault C, Toeg H, Nathan M, Wang ZJ, Roux JF, Secemsky E. Electrocardiographic monitoring for detecting atrial fibrillation after ischemic stroke or transient ischemic attack: systematic review and meta-analysis. *Circ Arrhythm Electrophysiol.* 2015;8(2):263-9.
11. Edvardsson N, Garutti C, Rieger G, et al. Unexplained syncope: implications of age and gender on patient characteristics and evaluation, the diagnostic yield of an implantable loop recorder, and the subsequent treatment. *Clin Cardiol.* Oct 2014;37(10):618-625. PMID 24890550
12. Favilla CG, Ingala E, Jara J, et al. Predictors of finding occult atrial fibrillation after cryptogenic stroke. *Stroke.* May 2015;46(5):1210-1215. PMID 25851771
13. Ferrick, A. M., Raj, S. R., Deneke, T., Kojodjojo, P., Lopez-Cabanillas, N., Abe, H., Boveda, S., Chew, D. S., Choi, J., Dagres, N., Dalal, A. S., Dechert, B. E., Frazier-Mills, C. G., Gilbert, O., Han, J. K., Hewit, S., Kneeland, C., Mirza, S. D., Mittal, S., . . . Varma, N. (2023). 2023 HRS/EHRA/APHRS/LAHR expert consensus statement on practical management of the remote device clinic. *Heart Rhythm*, 20(9), e92–e144. <https://doi.org/10.1016/j.hrthm.2023.03.1525>
14. Gladstone DJ, Dorian P, Spring M, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the EMBRACE trial. *Stroke.* 2015; 46(4):936-941.
15. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. *N Engl J Med.* 2014; 370(26):2467-2477.
16. Halcox JPJ, Wareham K, Cardew A, Gilmore M, Barry JP, Phillips C, Gravenor MB. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: the REHEARSE-AF Study. *Circulation.* 2017;136:1784– 1794 doi: 10.1161/CIRCULATIONAHA.117.030583.
17. Hayes, Inc. Evolving Evidence Review. *Zio Monitors (iRhythm) for Heart Rhythm Monitoring in Pediatrics.* Lansdale, PA: Hayes, Inc.; Sept 21, 2022.
18. Ip, J. E. (2019). Wearable devices for cardiac rhythm diagnosis and management. *Jama*, 321(4), 337-338
19. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. *Circulation.* 2019;140(2):e125-e151. Doi: <https://doi.org/10.1161/CIR.0000000000000665>
20. Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., ... & Van Wagoner, D. R. (2024). 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *Circulation*, 149(1), e1-e156.
21. Jorfida M, Antolini M, Cerrato E, et al. Cryptogenic ischemic stroke and prevalence of asymptomatic atrial fibrillation: a prospective study. *J Cardiovasc Med (Hagerstown).* 2016;17(12):863-869.
22. Kirchhof, P., Camm, A. J., Goette, A., Brandes, A., Eckardt, L., Elvan, A., Fetsch, T., Van Gelder, I. C., Haase, D., Haegeli, L. M., Hamann, F., Heidbüchel, H., Hindricks, G., Kautzner, J., Kuck, K., Mont, L., Ng, G. A., Rekosz, J., Schoen, N., . . . Breithardt, G. (2020). Early Rhythm-Control

- Therapy in Patients with Atrial Fibrillation. *New England Journal of Medicine*, 383(14), 1305–1316. <https://doi.org/10.1056/nejmoa2019422>
23. Kusumoto, F. M., Schoenfeld, M. H., Barrett, C., Edgerton, J. R., Ellenbogen, K. A., Gold, M. R., ... & Varosy, P. D. (2019). 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology*, 74(7), e51-e156.
 24. Mckenna, WJ. (May 2024). Arrhythmogenic right ventricular cardiomyopathy: Diagnostic evaluation and diagnosis. Waltham, MA. UpToDate.com. Retrieved from https://www.uptodate.com/contents/arrhythmogenic-right-ventricular-cardiomyopathy-diagnostic-evaluation-and-diagnosis?search=Arrhythmogenic%20right%20ventricular%20cardiomyopathy%3A%20diagnostic%20evaluation%20and%20diagnosis&source=search_result&selectedTitle=1%7E105&usage_type=default&display_rank=1#H576168529
 25. Ommen, S. R., Ho, C. Y., Asif, I. M., Balaji, S., Burke, M. A., Day, S. M., Dearani, J. A., Epps, K. C., Evanovich, L., Ferrari, V. A., Joglar, J. A., Khan, S. S., Kim, J. J., Kittleson, M. M., Krittanawong, C., Martinez, M. W., Mital, S., Naidu, S. S., Saberi, S., . . . Waldman, C. B. (2024). 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. *Circulation*, 149(23). <https://doi.org/10.1161/cir.0000000000001250>
 26. Padmanabhan, D., Kancharla, K., El-Harasis, M. A., Isath, A., Makkar, N., Noseworthy, P. A., ... & Kapa, S. (2019). Diagnostic and therapeutic value of implantable loop recorder: A tertiary care center experience. *Pacing and Clinical Electrophysiology*, 42(1), 38-45.
 27. Plas GJ, Bos J, Velthuis BO, et al. Diagnostic yield of external loop recording in patients with acute ischemic stroke or TIA. *J Neurol*. Mar 2015;262(3):682-688. PMID 25557280
 28. Podoleanu C, DaCosta A, Defaye P, et al. Early use of an implantable loop recorder in syncope evaluation: a randomized study in the context of the French healthcare system (FRESH study). *Arch Cardiovasc Dis*. 2014; 107(10):546-552.
 29. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. *N Engl J Med*. 2014; 370(26):2478-2486.
 30. Solomon MD, Yang J, Sung SH, et al. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. *BMC Cardiovasc Disord*. 2016;16:35.
 31. Soren Zoga MD, et al. Comprehensive Evaluation of Rhythm Monitoring Strategies in Screening for Atrial Fibrillation: Insights From Patients at Risk Monitored Long Term With an Implantable Loop Recorder Diederichsen. *Circulation Issue: Volume 141(19)*, 12 May 2020, p 1510-1522.
 32. Sposato LA, Cipriano LE, Saposnik G, et al. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol*. 2015; 14(4):377-387.

33. Steinberg, J. S., Varma, N., Cygankiewicz, I., Aziz, P., Balsam, P., Baranchuk, A., ... & Piotrowicz, R. (2017). 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. *Heart Rhythm*, 14(7), e55-e96.
34. Sutarnartpong P, Dharmasaroja PA, Ratanakorn D, Arunakul I. Atrial fibrillation and paroxysmal atrial fibrillation detection in patients with acute ischemic stroke. *J Stroke Cerebrovasc Dis*. 2014;23(5):1138-41.
35. Svendsen, J. H., Diederichsen, S. Z., Højberg, S., Krieger, D. W., Graff, C., Kronborg, C., Olesen, M. S., Nielsen, J. B., Holst, A. G., Brandes, A., Haugan, K. J., & Køber, L. (2021). Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. *The Lancet*, 398(10310), 1507–1516.
[https://doi.org/10.1016/s0140-6736\(21\)01698-6](https://doi.org/10.1016/s0140-6736(21)01698-6)
36. Towbin, J.A., McKenna, W.J., et al. 2019. HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. *Heart Rhythm Society Practice Guidelines* | Volume 16, Issue 11, E301-E372, November 01, 2019.
37. Tung CE, Su D, Turakhia MP, et al. Diagnostic Yield of Extended Cardiac Patch Monitoring in Patients with Stroke or TIA. *Front Neurol*. 2014;5:266. PMID 25628595
38. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol*. 2015;38(5):285-92.
39. Damiano RJ, Lawrance CP, Saint LL, et al. Detection of Atrial Fibrillation After Surgical Ablation: Conventional Versus Continuous Monitoring. *Ann Thorac Surg*. 2016;101(1):42-7.
40. Yang P, Pu L, Yang L, et al. Value of Implantable Loop Recorders in Monitoring Efficacy of Radiofrequency Catheter Ablation in Atrial Fibrillation. *Med Sci Monit*. 2016;22:2846-51.
41. Pecha S, Aydin MA, Ahmadzade T, et al. Implantable loop recorder monitoring after concomitant surgical ablation for atrial fibrillation (AF): insights from more than 200 continuously monitored patients. *Heart Vessels*. 2016;31(8):1347-53.
42. Ciconte G, Saviano M, Giannelli L, et al. Atrial fibrillation detection using a novel three-vector cardiac implantable monitor: the atrial fibrillation detect study. *Europace*. 2016;
43. Madias C. Ambulatory ECG monitoring. UpToDate.com. Last updated Aug 20, 2020. Retrieved June 2022 from
https://www.uptodate.com/contents/ambulatory-ecg-monitoring?search=implantable%20loop%20recorder&source=search_result&selectedTitle=2~36&usage_type=default&display_rank=2#H3
44. Marcelli E, Capucci A, Minardi G, Cercenelli L. Multi-Sense CardioPatch: A Wearable Patch for Remote Monitoring of Electro-Mechanical Cardiac Activity. *ASAIO J*. 2017;63(1):73-79.
45. Albers JW et al. Heart rhythm monitoring strategies for cryptogenic stroke. *J AHA* 2015;5(3)1-11.
46. Shen WK, et al. 2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Journal of the American College of Cardiology*. 2017;70(5):e39-e110. doi: 10.1016/j.jacc.2017.03.003.

47. Al-Khatib SM, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2018;138:e210–e271. doi: 10.1161/ CIR.0000000000000548.
48. Solomon MD, et al. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. *BMC Cardiovasc Disord*. 2016 Feb 17; 16:35. Epub 2016 Feb 17.
49. Steinberg, J. S., Varma, N., Cygankiewicz, I., Aziz, P., Balsam, P., Baranchuk, A., ... & Piotrowicz, R. (2017). 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. *Heart rhythm*, 14(7), e55-e96.

Clinical Guideline Revision / History Information

Original Date: 8/24/2017

Reviewed/Revised: 1/18/2018, 7/31/2018, 7/23/2019, 07/21/2020, 08/04/2021, 12/01/2021, 7/26/2022, 07/19/2023, 07/29/2024, 11/01/2025